专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2009159950A Immunoglobulin variant, method for using the same, and use thereof 审中-公开
标题翻译：免疫球蛋白变体，使用它们的方法及其用途
公开(公告)号：JP2009159950A
公开(公告)日：2009-07-23
申请号：JP2008297806
申请日：2008-11-21
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： ADAMS CAMELLIA W , CHAN ANDREW C , CROWLEY CRAIG W , LOWMAN HENRY B , NAKAMURA GERALD R , PRESTA LEONARD G
IPC分类号： C12N15/09 , A61K20060101 , A61K9/08 , A61K31/475 , A61K31/519 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/395 , A61K45/00 , A61K47/22 , A61K47/26 , A61K47/34 , A61K51/00 , A61P1/04 , A61P1/12 , A61P1/16 , A61P3/10 , A61P5/00 , A61P5/14 , A61P5/40 , A61P7/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P9/14 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/12 , A61P15/08 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/14 , A61P19/02 , A61P21/04 , A61P25/00 , A61P27/02 , A61P29/00 , A61P31/06 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07H21/04 , C07K14/705 , C07K16/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/63 , C12P21/08
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92
摘要： PROBLEM TO BE SOLVED: To provide an anti-CD20 antibody, and to provide a method for treating B-cell-associated diseases. SOLUTION: The anti-CD20 antibody is a monoclonal antibody and the antibody binding to the CD20 is humanized or chimeric. Humanized 2H7 variants include those that have amino acid substituents in FR and maturation variants having changes in grafted CDRs. The anti-CD20 antibody is effective in depleting B cells of primates in vivo and treatment of CD20 positive malignancies and autoimmune diseases can be carried out. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供抗CD20抗体，并提供治疗B细胞相关疾病的方法。解决方案：抗CD20抗体是单克隆抗体，与CD20结合的抗体是人源化或嵌合的。人源化2H7变体包括在FR中具有氨基酸取代基的那些变体和具有接枝CDR变化的成熟变体。抗CD20抗体在体内消耗灵长类动物的B细胞是有效的，可以进行CD20阳性恶性肿瘤和自身免疫性疾病的治疗。版权所有（C）2009，JPO＆INPIT

2. 发明专利

JP2009039122A Method for making multispecific antibody having heteromultimeric and common component 有权
标题翻译：制备具有异质性和共同成分的多重抗体的方法
公开(公告)号：JP2009039122A
公开(公告)日：2009-02-26
申请号：JP2008207339
申请日：2008-08-11
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： ARATHOON ROBERT , CARTER PAUL J , MERCHANT ANNE M , PRESTA LEONARD G
IPC分类号： C12N15/09 , C12P21/08 , A61K38/00 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/40 , C07K16/46 , C07K19/00 , C12N5/10
CPC分类号： C07K16/2863 , A61K38/00 , C07K1/22 , C07K16/2809 , C07K16/2812 , C07K16/46 , C07K16/468 , C07K2317/732 , Y10S435/972
摘要： PROBLEM TO BE SOLVED: To provide preparation of desired heteromultimeric multispecific antibodies. SOLUTION: A method of preparing heteromultimeres such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras is provided. The heteromultimers prepared by using the method are also provided. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally, the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供所需的异源多聚体多特异性抗体的制备。解决方案：提供了制备异种复合物例如双特异性抗体，双特异性免疫粘附素和抗体免疫粘附素嵌合体的方法。还提供了使用该方法制备的异源多聚体。通常，该方法提供具有与具有抗体结合结构域的每个异聚多肽相关联的共同轻链的多特异性抗体。另外，所述方法还包括在第一多肽的界面和第二多肽的界面处向多特异性抗体中引入特异性和互补的相互作用，以促进异源多聚体形成并阻碍同源多聚体形成; 和/或在第二多肽的界面处的第一多肽和相应的游离含硫醇残基的界面处的游离含硫醇残基，使得在第一和第二多肽之间形成非天然存在的二硫键。该方法允许相对于不想要的异多元反应物和同源多聚体增强所需异源多聚体的形成。版权所有（C）2009，JPO＆INPIT

3. 发明专利

JP2008291036A Immunoglobulin variant 有权
标题翻译：免疫球蛋白变体
公开(公告)号：JP2008291036A
公开(公告)日：2008-12-04
申请号：JP2008158861
申请日：2008-06-18
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： CARTER PAUL J , PRESTA LEONARD G
IPC分类号： C07K16/00 , C07K16/46 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/00 , C07K16/18 , C07K16/28 , C07K16/32 , C07K16/40 , C07K19/00 , C12N15/02 , C12N15/09 , C12N15/13 , C12P21/08 , C12R1/19 , C12R1/91 , G06F15/00
CPC分类号： G06F15/00 , A61K38/00 , C07K16/28 , C07K16/2809 , C07K16/32 , C07K16/465 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/732 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide a variant immunoglobulin, especially a humanized antibody polypeptide with a method for producing and use of it, further a consensus immunoglobulin sequence and a structural model. SOLUTION: The variant immunoglobulin is obtained by obtaining an import antibody variable domain for making a humanized antibody comprising amino acid sequence of a non-human, import (transferred) antibody and a human antibody, and an amino acid sequence of a variable consensus domain, substituting an imported CDR amino acid sequence in place of a corresponding human CDR amino acid sequence, and determining if the non-homologous import amino acid residue is reasonably expected to have at least one of the following effects: 1. non-covalently binds antigen directly; 2. interacts with a CDR; and 3. participates in the VL-VH interface; substituting that residue for the corresponding amino acid residue in the consensus antibody FR sequence. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供变体免疫球蛋白，特别是人源化抗体多肽与其制备和使用方法，进一步的共有免疫球蛋白序列和结构模型。解决方案：通过获得用于制备包含非人，进口（转移）抗体和人抗体的氨基酸序列的人源化抗体的进口抗体可变结构域和变量的氨基酸序列获得变体免疫球蛋白取代进口的CDR氨基酸序列代替相应的人CDR氨基酸序列，并确定非同源进口氨基酸残基是否合理地预期具有以下作用中的至少一种：1.非共价的直接结合抗原; 2.与CDR交互; 和3.参与VL-VH接口; 用该残基代替共有抗体FR序列中相应的氨基酸残基。版权所有（C）2009，JPO＆INPIT

4. 发明专利

JP2009055902A IMPROVED ANTI-IgE ANTIBODY AND METHOD OF IMPROVING POLYPEPTIDE 有权
标题翻译：改进的抗IgE抗体和改善多肽的方法
公开(公告)号：JP2009055902A
公开(公告)日：2009-03-19
申请号：JP2008151343
申请日：2008-06-10
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： LOWMAN HENRY B , PRESTA LEONARD G , JARDIEU PAULA M , LOWE JOHN
IPC分类号： C12N15/02 , C12P21/08 , A61K38/00 , A61K39/395 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07K16/00 , C07K16/42 , C12N15/09 , C12N15/13
CPC分类号： C07K16/00 , A61K38/00 , C07K16/4291 , C07K2317/24 , Y10S424/81 , Y10S530/868
摘要： PROBLEM TO BE SOLVED: To provide a method for adjusting the affinity of a polypeptide to a target molecule. SOLUTION: The method includes (1) the identification of aspartyl residues which are prone to isomerization; and (2) the substitution of alternative residues and the screening of the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment, the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供一种调节多肽与靶分子的亲和力的方法。解决方案：该方法包括（1）易于异构化的天冬氨酰残基的鉴定; 和（2）替代残基并筛选得到的突变体对靶分子的亲合力。在优选的实施方案中，取代残基的方法是用噬菌体展示（AMPD）进行亲和力成熟。在另一个优选的实施方案中，多肽是抗体，靶分子是抗原。在另一个优选的实施方案中，抗体是抗IgE，靶分子是IgE。在另一个实施方案中，本发明涉及对IgE具有改善的亲和力的抗IgE抗体。版权所有（C）2009，JPO＆INPIT

5. 发明专利

JP2008113664A Human trk receptor and neurotrophic factor inhibitors 有权
标题翻译：人类trk受体和神经营养因子抑制剂
公开(公告)号：JP2008113664A
公开(公告)日：2008-05-22
申请号：JP2007317771
申请日：2007-12-07
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： PRESTA LEONARD G , SHELTON DAVID L , URFER ROMAN
IPC分类号： C12N15/09 , G01N33/53 , A61K38/00 , A61K38/55 , A61K39/395 , A61P1/00 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P25/18 , A61P25/28 , A61P29/00 , A61P35/00 , C07H21/04 , C07K14/705 , C07K14/71 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N15/02 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68
CPC分类号： C07K19/00 , A61K38/00 , C07K14/71 , C07K2319/00 , C07K2319/30
摘要： PROBLEM TO BE SOLVED: To provide effective inhibitors of neurotrophic factor biological activity. SOLUTION: An isolated human trkB or trkC polypeptide includes an amino acid sequence of a polypeptide selected from the group consisting of (a) a native sequence human trkB or trkC polypeptide, (b) a polypeptide having at least 95% amino acid sequence identity with a native sequence human trkB or trkC polypeptide, exhibiting a biological property of a native human trkB or trkC polypeptide, and being non-immunogenic in the human, and (c) a fragment of the polypeptide of (a) or (b) exhibiting a biological property of a native human trkB or trkC polypeptide, and being non-immunogenic in the human. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：提供有效的神经营养因子生物活性抑制剂。解决方案：分离的人trkB或trkC多肽包括选自（a）天然序列人trkB或trkC多肽的多肽的氨基酸序列，（b）具有至少95％氨基酸的多肽具有天然序列人trkB或trkC多肽的序列同一性，显示天然人trkB或trkC多肽的生物学特性，并且在人中是非免疫原性的，和（c）（a）或（b）的多肽的片段）表现出天然人类trkB或trkC多肽的生物学特性，并且在人体中是非免疫原性的。版权所有（C）2008，JPO＆INPIT

6. 发明专利

JP2006166924A Human trk receptor and neurotrophic factor inhibitor 审中-公开
标题翻译：人TRK受体和神经营养因子抑制剂
公开(公告)号：JP2006166924A
公开(公告)日：2006-06-29
申请号：JP2006019882
申请日：2006-01-27
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： PRESTA LEONARD G , SHELTON DAVID L , URFER ROMAN
IPC分类号： C12N15/09 , G01N33/53 , A61K38/00 , A61K38/55 , A61K39/395 , A61P1/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P15/00 , A61P25/00 , A61P25/04 , A61P25/18 , A61P25/28 , A61P29/00 , A61P35/00 , A61P43/00 , C07H21/04 , C07K14/705 , C07K14/71 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68
CPC分类号： C07K19/00 , A61K38/00 , C07K14/71 , C07K2319/00 , C07K2319/30
摘要： PROBLEM TO BE SOLVED: To provide an inhibitor effective for biological activity of neurotrophic factors. SOLUTION: Disclosed is an isolated human trkB or trkC polypeptide comprising an amino acid sequence of a polypeptide selected from the group consisting of : (a) a native sequence human trkB or trkC polypeptide, (b) a polypeptide having at least 95% amino acid sequence identity with a native sequence human trkB or trkC polypeptide, exhibiting a biological property of a native human trkB or trkC polypeptide, and being non-immunogenic in the human, and (c) a fragment of a polypeptide of (a) or (b) exhibiting a biological property of a native human trkB or trkC polypeptide, and being non-immunogenic in the human. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供对神经营养因子的生物活性有效的抑制剂。解决方案：公开了一种分离的人trkB或trkC多肽，其包含选自以下的多肽的氨基酸序列：（a）天然序列人trkB或trkC多肽，（b）具有至少95个具有天然序列人trkB或trkC多肽的氨基酸序列同一性，表现出天然人trkB或trkC多肽的生物学特性，并且在人体中是非免疫原性的，和（c）（a）的多肽的片段，或（b）显示天然人类trkB或trkC多肽的生物学特性，并且在人体中是非免疫原性的。版权所有（C）2006，JPO＆NCIPI

7. 发明专利

JP2005000169A Immunoglobulin variant 审中-公开
标题翻译：免疫球蛋白变体
公开(公告)号：JP2005000169A
公开(公告)日：2005-01-06
申请号：JP2004168507
申请日：2004-06-07
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： CARTER PAUL J , PRESTA LEONARD G
IPC分类号： C07K16/00 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/00 , C07K16/18 , C07K16/28 , C07K16/32 , C07K16/46 , C07K19/00 , C12N15/09 , C12N15/13 , C12P21/08 , C12R1/19 , C12R1/91 , G06F15/00
CPC分类号： G06F15/00 , A61K38/00 , C07K16/28 , C07K16/2809 , C07K16/32 , C07K16/465 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/732 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide humanized antibody polypeptides and methods for their preparation and use, and to provide consensus immunoglobulin sequences and structural models. SOLUTION: The humanized antibody is obtained by (a) obtaining the amino acid sequences of consensus human variable domain of at least a part of an import variable domain and of a human heavy chain immunoglobulin sub group, (b) identifying Complementarity Determining Region (CDR) amino acid sequences in the import and the human amino variable domain sequences, (c) substituting an import CDR amino acid sequence for the corresponding human CDR amino acid sequence, (d) aligning the amino acid sequences of a Framework Region (FR) of the import antibody and the corresponding FR of the consensus antibody, (e) identifying import antibody FR residues in the aligned FR sequences that are non-homologous to the corresponding consensus antibody residues, (f) substituting the amino acid sequence of the non-homologous import antibody with corresponding residues of amino acid residues in the consensus FR antibody sequence. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：提供人源化抗体多肽及其制备和使用方法，并提供一致的免疫球蛋白序列和结构模型。解决方案：通过（a）获得进口可变结构域和人重链免疫球蛋白亚组的至少一部分的共有人可变结构域的氨基酸序列获得人源化抗体，（b）鉴定互补决定导入的氨基酸序列和人类氨基酸可变区序列中的区域（CDR）氨基酸序列，（c）用进口CDR氨基酸序列取代相应的人CDR氨基酸序列，（d）使框架区的氨基酸序列 FR）和（e）鉴定与对应的共有抗体残基不同源的比对FR序列中的进一步抗体FR残基，（f）取代所述导入抗体的氨基酸序列非同源进口抗体，在共有FR抗体序列中具有相应氨基酸残基残基。版权所有（C）2005，JPO＆NCIPI

8. 发明专利

JP2009131257A Anti-interferon-α antibody 有权
标题翻译：抗干扰素-α抗体
公开(公告)号：JP2009131257A
公开(公告)日：2009-06-18
申请号：JP2008298277
申请日：2008-11-21
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： CHUNTHARAPAI ANAN , KIM JIN K , PRESTA LEONARD G , STEWART TIMOTHY
IPC分类号： C12N15/09 , G01N33/53 , A61K39/395 , A61P3/10 , A61P5/14 , A61P5/50 , A61P17/00 , A61P37/02 , A61P37/06 , C07K16/24 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N5/16 , C12N5/20 , C12N15/02 , C12N15/13 , C12P21/02 , C12P21/08 , G01N33/564 , G01N33/68
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/564 , G01N33/6866 , G01N2333/56 , G01N2800/042 , G01N2800/24
摘要： PROBLEM TO BE SOLVED: To provide the use of an anti-interferon-α antibody relating generally to the generation and characterization of a neutralizing anti-IFN-α antibody with broad reactivity against various IFN-α subtypes in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). SOLUTION: Provided are anti-IFN-α monoclonal antibodies bonding at least with IFNα subtypes IFNα1, IFNα2, IFNα4, IFNα5, IFNα8, IFNα10 and IFNα21 and neutralizing biological activity. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：为了提供在诊断和治疗中对各种IFN-α亚型具有广泛反应性的中和抗-IFN-α抗体的产生和表征的抗干扰素-α抗体的使用与IFN-α表达增加相关的疾病，特别是自身免疫疾病如胰岛素依赖性糖尿病（IDDM）和系统性红斑狼疮（SLE）。提供至少与IFNα亚型IFNα1，IFNα2，IFNα4，IFNα5，IFNα8，IFNα10和IFNα21结合的抗IFN-α单克隆抗体，并中和生物活性。版权所有（C）2009，JPO＆INPIT

9. 发明专利

JP2006075165A HUMAN trk RECEPTOR AND NEUROTROPHIC FACTOR INHIBITOR 有权
标题翻译：人类trk受体和神经营养因子抑制剂
公开(公告)号：JP2006075165A
公开(公告)日：2006-03-23
申请号：JP2005260642
申请日：2005-09-08
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： PRESTA LEONARD G , SHELTON DAVID L , URFER ROMAN
IPC分类号： C12N15/09 , G01N33/53 , A61K38/00 , A61K38/55 , A61K39/395 , A61P1/00 , A61P1/18 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P25/04 , A61P25/08 , A61P25/18 , A61P25/28 , A61P29/00 , A61P35/00 , C07H21/04 , C07K1/22 , C07K14/705 , C07K14/71 , C07K16/18 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68
CPC分类号： C07K19/00 , A61K38/00 , C07K14/71 , C07K2319/00 , C07K2319/30
摘要： PROBLEM TO BE SOLVED: To provide human trkB and trkC proteins to understand the rolls of trk and neurotrophin activities more in various human pathological conditions. SOLUTION: Provided are the kimera polypeptide containing a trk receptor amino acid sequence fused with an immunoglobulin sequence, the medicinal composition containing the kimera peptide, the nucleotide sequence encoding the kimera peptide, the expression vector, the host cell, the double specific molecule of an immunoadhesin containing the amino acid sequence of the trk receptor, a medicinal composition containing the double specific molecule, the method for purifying a neurotrophic factor using the double specific molecule, and the method for diagnosing the pathological conditions characterized by the excess or insufficient expression of the neurotrophic factor, involving bringing the biological sample containing the neurotrophic factor into contact with the trk receptor polypeptide capable of bonding to the neurotrophic factor and labeled so as to be detected, and detecting the label bonded thereto. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：在各种人类病理状况下，提供人类trkB和trkC蛋白质以了解更多的trk和神经营养因子活性。解决方案：提供含有与免疫球蛋白序列融合的trk受体氨基酸序列的基因多肽，含有基因多肽的药物组合物，编码基因拉肽的核苷酸序列，表达载体，宿主细胞，双特异性含有trk受体的氨基酸序列的免疫粘附素的分子，含有双特异性分子的药物组合物，使用该双特异性分子的神经营养因子的纯化方法，以及用于诊断以过量或不足为特征的病理状态的方法神经营养因子的表达，包括将含有神经营养因子的生物样品与能够与神经营养因子结合的trk受体多肽接触并标记以便被检测，并检测与其结合的标记。版权所有（C）2006，JPO＆NCIPI

10. 发明专利

JP2004049234A Selectin variant 有权
公开(公告)号：JP2004049234A
公开(公告)日：2004-02-19
申请号：JP2003179641
申请日：2003-06-24
申请人： Genentech Inc , ジェネンテック・インコーポレーテッドGenentech,Inc.
发明人： ERBE DAVID V , LASKY LAURENCE A , PRESTA LEONARD G
IPC分类号： C12N15/02 , A61K38/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , C07K14/47 , C07K14/705 , C07K14/78 , C07K16/00 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/00 , C12N15/01 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12R1/91
CPC分类号： C07K14/70564 , A61K38/00 , C07K2319/035 , C07K2319/30 , C07K2319/32
摘要： PROBLEM TO BE SOLVED: To provide a selectin variant having an amino acid variation at a site of selectin lectin domain amino acid sequence in a region defined by a bonding site recognized by a blocking monoclonal antibody against the corresponding selectin having an unchanged lectin domain. SOLUTION: The nucleotide sequence cording the variant, the expression vector containing the nucleotide sequence and a host cell transformed by the expression vector are provided. COPYRIGHT: (C)2004,JPO

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式